Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD3 known ✓ | O94806 | 5/20 | 0.97 |
| ▸ | PRKCG known ✓ | P05129 | 5/20 | 0.97 |
| ▸ | PRKCB known ✓ | P05771 | 5/20 | 0.97 |
| ▸ | PRKCA known ✓ | P17252 | 5/20 | 0.97 |
| ▸ | PRKCH known ✓ | P24723 | 5/20 | 0.97 |
| ▸ | PRKCI known ✓ | P41743 | 5/20 | 0.97 |
| ▸ | PRKCE known ✓ | Q02156 | 5/20 | 0.97 |
| ▸ | PRKCQ known ✓ | Q04759 | 5/20 | 0.97 |
| ▸ | PRKCZ known ✓ | Q05513 | 5/20 | 0.97 |
| ▸ | PRKCD known ✓ | Q05655 | 5/20 | 0.97 |
| ▸ | PRKD1 known ✓ | Q15139 | 5/20 | 0.97 |
| ▸ | ROCK2 known ✓ | O75116 | 10/20 | 0.91 |
| ▸ | ROCK1 known ✓ | Q13464 | 9/20 | 0.91 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.88 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.88 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.88 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.88 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.88 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.88 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30084459 | 1.00 | PRKD3 (0.97) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| Hydrochloric Acid SCHEMBL1165381 | 1.00 | PRKD3 (0.97) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| Hydrochloric Acid SCHEMBL29629288 | 1.00 | PRKD3 (0.97) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| Hydrochloric Acid SCHEMBL29968274 | 1.00 | PRKD3 (0.97) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| Hydrochloric Acid SCHEMBL31655516 | 0.99 | PRKD3 (0.95) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL29968762 | 0.99 | PRKD3 (1.00) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL1272907 | 0.99 | PRKD3 (1.00) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL30422637 | 0.99 | PRKD3 (1.00) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| Fasudil SCHEMBL6032335 | 0.95 | ROCK2 (1.00) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| Fasudil SCHEMBL317082 | 0.95 | ROCK2 (1.00) | PRKD3PRKCGPRKCBPRKCAPRKCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | claimed |
| WO-2023039578-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION (US) | 2023-03-16 | — | — | WO | claimed |
| US-20250304916-A1 | METHODS AND COMPOSITIONS FOR GENERATING VASCULAR LEPTOMENINGEAL CELLS | TRAILHEAD BIOSYSTEMS INC (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | disclosed |
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LTD (AU) | 2025-01-16 | — | — | US | disclosed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | disclosed |
| EP-3609500-B1 | TREATMENT OF ADIPOCYTES | MELIOR PHARMACEUTICALS I INC (US) | 2024-11-13 | — | — | EP | disclosed |
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | disclosed |
| US-12064432-B2 | Treatment of adipocytes | MELIOR PHARMACEUTICALS I, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| CN-117999073-A | Use of nadolol to treat chronic obstructive pulmonary disease by blocking the inhibitor protein-2 pathway | 慢性呼吸道治疗有限公司 | 2024-05-07 | — | — | CN | disclosed |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | disclosed |
| US-20230149404-A1 | Treatment Of Adipocytes | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2023-05-18 | — | — | US | disclosed |
| WO-2023039578-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION (US) | 2023-03-16 | — | — | WO | disclosed |
| US-11534442-B2 | Treatment of adipocytes | MELIOR PHARMACEUTICALS I, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| WO-2022192252-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2022-09-15 | — | — | WO | disclosed |
| EP-1766416-A1 | USE OF STANDARDS FOR MONITORING ALTERATIONS OF PEPTIDE AND PROTEIN SAMPLES | DIGILAB BioVisioN GmbH (DE) | 2007-03-28 | — | — | EP | disclosed |
| EP-1619503-A1 | Use of standards for monitoring alterations of peptide and protein samples | BioVisioN AG (DE) | 2006-01-25 | — | — | EP | disclosed |
| WO-2006005622-A1 | USE OF STANDARDS FOR MONITORING ALTERATIONS OF PEPTIDE AND PROTEIN SAMPLES | DIGILAB BIOVISION GMBH (DE) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149404-A1 | Treatment Of Adipocytes | LIPG, LPL, PNLIP | PRKD3 146/4885PRKCG 59/4885PRKCB 92/4885 |
| US-12064432-B2 | Treatment of adipocytes | LIPG, LPL, PNLIP | PRKD3 146/4885PRKCG 59/4885PRKCB 92/4885 |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | TP53, CD4, MCL1 | PRKD3 2542/4885PRKCG 1138/4885PRKCB 1254/4885 |
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | ARRB1, ADRB2, ADRB1 | PRKD3 1681/4885PRKCG 586/4885PRKCB 183/4885 |
| US-11534442-B2 | Treatment of adipocytes | LIPG, LPL, PNLIP | PRKD3 146/4885PRKCG 59/4885PRKCB 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.